Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury.
Authors
Mowforth, Oliver D
Bhatti, Aniqah I
Adeeko, Sylva
Akhbari, Melika
Dilworth, Rory
Osunronbi, Temidayo
Ottewell, Luke
Robinson, Sophie
Suresh, Gayathri
Waheed, Unaiza
Walker, Benn
Smith, Lara
Davies, Benjamin M
Publication Date
2021-12Journal Title
Spinal Cord
ISSN
1362-4393
Publisher
Springer Science and Business Media LLC
Volume
59
Issue
12
Pages
1221-1239
Language
en
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Bhatti, F. I., Mowforth, O. D., Butler, M. B., Bhatti, A. I., Adeeko, S., Akhbari, M., Dilworth, R., et al. (2021). Systematic review of the impact of cannabinoids on neurobehavioral outcomes in preclinical models of traumatic and nontraumatic spinal cord injury.. Spinal Cord, 59 (12), 1221-1239. https://doi.org/10.1038/s41393-021-00680-y
Abstract
STUDY DESIGN: Systematic review. OBJECTIVES: To evaluate the impact of cannabinoids on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic spinal cord injury (SCI), with the aim of determining suitability for clinical trials involving SCI patients. METHODS: A systematic search was performed in MEDLINE and Embase databases, following registration with PROPSERO (CRD42019149671). Studies evaluating the impact of cannabinoids (agonists or antagonists) on neurobehavioral outcomes in preclinical models of nontraumatic and traumatic SCI were included. Data extracted from relevant studies, included sample characteristics, injury model, neurobehavioural outcomes assessed and study results. PRISMA guidelines were followed and the SYRCLE checklist was used to assess risk of bias. RESULTS: The search returned 8714 studies, 19 of which met our inclusion criteria. Sample sizes ranged from 23 to 390 animals. WIN 55,212-2 (n = 6) and AM 630 (n = 8) were the most used cannabinoid receptor agonist and antagonist respectively. Acute SCI models included traumatic injury (n = 16), ischaemia/reperfusion injury (n = 2), spinal cord cryoinjury (n = 1) and spinal cord ischaemia (n = 1). Assessment tools used assessed locomotor function, pain and anxiety. Cannabinoid receptor agonists resulted in statistically significant improvement in locomotor function in 9 out of 10 studies and pain outcomes in 6 out of 6 studies. CONCLUSION: Modulation of the endo-cannabinoid system has demonstrated significant improvement in both pain and locomotor function in pre-clinical SCI models; however, the risk of bias is unclear in all studies. These results may help to contextualise future translational clinical trials investigating whether cannabinoids can improve pain and locomotor function in SCI patients.
Keywords
Review Article, /692/617/375/1824, /692/308/2778, review-article
Sponsorship
NIHR Clinical Doctoral Research Fellowship.
Funder references
Department of Health (via National Institute for Health Research (NIHR)) (NIHR300696)
National Institute for Health Research (NIHR300696)
Identifiers
s41393-021-00680-y, 680
External DOI: https://doi.org/10.1038/s41393-021-00680-y
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331464
Rights
Licence:
http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk